Market Access News | pharmaphorum

News

Advanz wins stay on EU revocation of Ocaliva license

There's been another twist to the tale of Advanz Pharma's efforts to keep its primary biliary cholangitis (PBC) therapy Ocaliva on the market in the EU.

News

Trial of Click's DTx for migraine sets up FDA filing

Click Therapeutics' digital therapeutic (DTx) for migraine has hit the mark in a late-stage study using an endpoint commonly used to test drug therapies, which it claims is a first for the

News

Novartis' oral PNH drug Fabhalta rolls out in England, Wales

Novartis' targeted Factor B inhibitor Fabhalta – the first oral monotherapy for rare disease paroxysmal nocturnal haemoglobinuria (PNH) – has been cleared by NICE for use by the NHS in Engl

News

Advanz Pharma's bid to keep Ocaliva on EU market fails

The European Commission has followed the advice of its human medicines committee and revoked the conditional marketing authorisation for Advanz Pharma's Ocaliva therapy for primary biliary

News

As mpox cases rise over 18,000, UNICEF tenders for vaccines

The United Nations Children's Fund (UNICEF) has issued an emergency tender to secure mpox vaccines for countries dealing with the brunt of the outbreak, in collaboration with the Gavi vacci

News

Emergent Bio gets FDA green light for mpox vaccine

Emergent BioSolutions has been given FDA approval to extend the indications for its smallpox vaccine ACAM2000 to include the prevention of mpox, currently deemed a public health emergency b

Advanz wins stay on EU revocation of Ocaliva license

Trial of Click's DTx for migraine sets up FDA filing

Novartis' oral PNH drug Fabhalta rolls out in England, Wales

Advanz Pharma's bid to keep Ocaliva on EU market fails

As mpox cases rise over 18,000, UNICEF tenders for vaccines

Emergent Bio gets FDA green light for mpox vaccine

FDA kicks off review of Takeda's narcolepsy hopeful

How to meet your physicians where they are online

News

Editor's Picks